Sugi Predict

Sugi Predict / Compounds / SCHEMBL214490

SCHEMBL214490

SCHEMBL214490

CCCCCCOC(=O)[C@H](C)N

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 1/20 0.55
▸ EPHX1 P07099 1/20 0.52
▸ TSHR P16473 3/20 0.50
▸ HTR2C P28335 1/20 0.49
▸ HCAR2 Q8TDS4 1/20 0.47
▸ RAD52 P43351 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ FAAH O00519 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ ACHE P22303 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5271653 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL18378763 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL10347198 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL13797804 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL15796773 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL5271657 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL4679055 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL4206354 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL18378981 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2
SCHEMBL3880771 1.00 NAAA (0.55) NAAAEPHX1TSHRHTR2CHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107206254-A Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel disease 领导医疗有限公司 2017-09-26 — — CN claimed
CN-1993141-A Induction of immune response against Streptococcus pneumoniae polysaccharides EPIMMUNE INC (US) 2007-07-04 — — CN claimed
US-12030903-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2024-07-09 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
CN-114644651-A Process for producing aryloxyphosphorylated amino acid ester compound 中国人民解放军军事科学院军事医学研究院 2022-06-21 — — CN disclosed
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-03-22 — — US disclosed
US-20200308231-A9 SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-10-01 — — US disclosed
EP-3390413-B1 ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS MERCK SHARP & DOHME (US) 2020-08-19 — — EP disclosed
US-10450335-B2 Antiviral oxime phosphoramide compounds MERCK SHARP & DOHME CORP. (US) 2019-10-22 — — US disclosed
US-20190300576-A1 SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-10-03 — — US disclosed
CN-1124282-C Conformationally constrained backbone cyclized somatostatin analogs PEPTOR LTD (IL) 2003-10-15 — — CN disclosed
CN-1427725-A Casein derived peptides and therapeutic uses thereof CHAY 13 MEDICAL RES GROUP N V (NL) 2003-07-02 — — CN disclosed
CN-1416354-A Vascular endothelial growth factor 2 HUMAN GENOME SCIENCES INC (US) 2003-05-07 — — CN disclosed
EP-1117669-B1 ANTIVIRAL PURINE DERIVATIVES UNIV CARDIFF (GB) 2003-01-29 — — EP disclosed
US-20010031745-A1 Antiviral purine derivatives UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2001-10-18 — — US disclosed
CN-1310626-A Hybrid polypeptides with enhanced pharmacokinetic properties TRIMERIS INC (US) 2001-08-29 — — CN disclosed
EP-1117669-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) 2001-07-25 — — EP disclosed
WO-2000018775-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2000-04-06 — — WO disclosed
CN-1231672-A Conformationally constrained backbone cyclized somatostatin analogs PEPTOR LTD (IL) 1999-10-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 NAAA 2201/4885EPHX1 2027/4885TSHR 2321/4885
US-20200308231-A9 SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES TP53, MDM2, MDM4 NAAA 4282/4885EPHX1 4602/4885TSHR 4784/4885
US-20190300576-A1 SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES TP53, MDM2, MDM4 NAAA 4282/4885EPHX1 4602/4885TSHR 4784/4885
US-12030903-B2 Antiviral compounds EIF2AK2, MAVS, DUT NAAA 1543/4885EPHX1 2615/4885TSHR 4684/4885
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries TP53, MDM2, MDM4 NAAA 4282/4885EPHX1 4602/4885TSHR 4784/4885
US-10450335-B2 Antiviral oxime phosphoramide compounds TYMP, MTAP, POLR2E NAAA 800/4885EPHX1 1106/4885TSHR 4050/4885
US-20010031745-A1 Antiviral purine derivatives PNP, TYMP, MTAP NAAA 355/4885EPHX1 1692/4885TSHR 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.